Waters Corporation WAT
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Waters Corporation gets an algorithmic score of 57/100. It trades at 443.26 $, with a bullish technical trend (RSI 68.8) and 35.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
Weaknesses
- Low ROE (1.9%).
Fundamentals
| P/E | 112.22 |
| Forward P/E | 26.79 |
| PEG | 1.57 |
| P/B | 2.87 |
| EV/EBITDA | 33.39 |
| P/S | 9.37 |
| ROE % | 1.92 |
| ROA % | 3.56 |
| Gross margin % | 56.34 |
| Operating margin % | 9.42 |
| Net margin % | 3.59 |
| Revenue growth % (y/y) | 113.40 |
| Revenue CAGR % | 2.12 |
| Earnings CAGR % | -3.17 |
| Debt/Equity % | 36.05 |
| Current ratio | 1.86 |
| FCF yield % | 1.24 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +6.9 % |
| 3 months | +18.2 % |
| 6 months | +51.1 % |
| YTD | +16.1 % |
| 1 year | +52.0 % |
| 3 years | +64.8 % |
| 5 years | +13.0 % |
Risk
| 1-year volatility | 35.8 % |
| Beta | 1.00 |
| 5-year max drawdown | -41.1 % |
| Sharpe 1A | 1.24 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.